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The solid-phase synthesis of a library of arginine-containing lipid transfection agents on high-loading beads
is described. The transfection activity of the cationic lipids was determined using compound cleaved from
single beads (single-bead screening) and showed, in some cases, comparable or higher DNA transfection
activities as compared to commercially available reagents. Lipids with one arginine headgroup and a
cholesterol tail were found to be the most active, even though their DNA binding strength (retardation
assays) was relatively weak. Single-bead screening of transfection activity facilitates the rapid analysis of
libraries of transfection reagents and will allow the rapid optimization of gene delivery into cells, both in
culture and in vivo.
Introduction
Over recent years combinatorial chemistry methods have
revolutionized the synthesis of small organic compounds.1
Many strategies have been applied, but two methods, parallel
and split-and-mix synthesis, occupy a dominant position. Of
these two approaches, split-and-mix synthesis is certainly
more compelling in terms of the time and the overall cost
and the size of libraries that can be prepared,2 but parallel
synthesis3 is the major method currently used in library
generation. The one-bead/one-compound combinatorial ap-
proach is, however, highly efficient,4 enabling the generation
of thousands or millions of compounds in only a small
number of synthetic steps, although the quantity of material
on a single bead is relatively limited, and identification of
active compounds at the single bead level can be difficult.
These problem can be solved first by increasing the loading
of each single bead and second by developing sensitive
methods to screen for compound activity.
Methods to increase bead loading for single-compound/
single-bead stock solution screening were first reported in
1997 using a process of PAMAM dendrimerization,5 and
more recently, AB3-type isocyanate monomers have proven
to be high advantageous building blocks to increase the
loading of a solid support due to their high branching
multiplicity and the presence of a reactive isocyanate
group.6-8 Thus, repeated coupling of monomer 1 (Figure 1)
onto 200-250-ím aminomethyl polystyrene beads (13 nmol/
bead) increases the loading of the beads by 2.8-fold (36 nmol/
bead) and 6.9-fold (90 nmol/bead) (generation 1.0 and 2.0),
respectively.8 In this paper, transfection agents were syn-
thesized on these high-loading beads using solid-phase
synthesis to allow sufficient compound to be released from
single beads for transfection screening.
There is still a significant need for the development of
new, nonviral, transfection reagents for the study of gene
function using cells in culture9 and for therapeutic gene
delivery in vivo.10 Cationic lipids for transfection generally
contain a cationic headgroup attached to a hydrophobic tail.
Arginine-containing lipids have been shown to transfect
COS-7 cells,11 with the guanidinium group interacting with
the negatively charged phosphate groups of the oligonucle-
otide and also presumably with the cell membrane. Short
oligomers of arginine have also been shown to enter cells
more rapidly than the corresponding oligomers of lysine,
histidine, ornithine, or citrulline.12 Thus, a library of cationic
lipids possessing a guanidine headgroup linked to various
aliphatic or steroidal tail groups was synthesized. Compounds
were cleaved from single beads and tested for transfection
activity and cytotoxicity and other factors affecting the
activity of the most efficient compounds were determined.
Results and Discussion
Synthesis of Transfection Compounds on High-Loading
Beads. High-loading beads of type 2 (generation 1.0) were
generated using an AB3-type isocyanate monomer (1)8
(Figure 1) attached directly onto the aminomethyl polystyrene
resin.
Scaffolds with one, two, or three arginine headgroups (5-
7) were synthesized on these beads (Scheme 1) using Fmoc
chemistry. Thus high-loading beads (2, Gen 1.0) were reacted
with the commercially available Fmoc Knorr linker 3, which
was Fmoc-deprotected to give 4, which was coupled with
commercially available Fmoc-arginine(Boc)2-OH, followed
by Fmoc deprotection. The process was repeated to give 6
and 7 (Scheme 1).
The spacer between the cationic headgroup and the
hydrophobic moiety plays a key role in transfection activity.13
It has been shown that cationic lipids containing biodegrad-
able ester spacers have high transfection efficiency and low
cytotoxicity,14,15 whereas Kawaura16 found that the transfec-
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tion efficiency was dependent on the length of the spacer
between the cationic headgroup and the hydrophobic tail.
Thus, four different commercially available amino acids
spacers, with 1, 2, 3, or 5 carbons between the amine and
carboxylic acid functionality (Figure 2) were attached to 5-7
to afford the arginine scaffolds with various spacers 8-11
(Scheme 2).
With the 15 scaffolds in hand (3 scaffolds without spacers
(5-7, Scheme 1) and 12 scaffolds with spacers (8-11,
Scheme 2)), a small library was constructed as shown in
Scheme 3 (15 arginine scaffolds  4 hydrophobic tails )
60 compounds) to enable initial evaluation of the single bead
screening methods. Cleavage and concomitant deprotection
with 90% TFA in CH2Cl2 from a single bead furnished
sufficient material for LC and MS analysis (high-resolution
mass spectrometry characterization was performed on the
library). The average purity of the compounds was 83%
(HPLC).
Gel Retardation Assay.17 To assess the relative binding
activities of the transfection compounds for DNA, agarose
gel electrophoresis of cationic lipid/DNA complexes was
performed using compound cleaved from a single bead, and
38 of the 60 compounds completely bound plasmid DNA
(Figure 4). The number of arginine residues and the type of
hydrophobic tail had a major effect on complex formation,
but the spacer appeared to have little effect. Transfection
compounds containing one arginine (A1, 2, 4; B1, 2, 4; C1,
2, 4; D1, 2, 4; and E1, 2, 4; Scheme 3 and Table 1) did not
bind DNA unless an oleyl tail group was present (A3, B3,
C3, D3 and E3), irrespective of the spacer employed.
Transfection compounds containing two arginines and ali-
phatic tails (F1-F3, G1-G3, H1-H3, A5-A7, and B5-
B7) all retarded the DNA, unlike compounds with two
arginines and a cholesterol tail (F4, G4, H4, A8, B8).
Figure 1. Structures of AB3-type monomer and high-loading polystyrene (PS) bead (generation 1.0).
Scheme 1a
a Reagents and conditions: (a) linker 3 (1.5 equiv), DIC (1.5 equiv), HOBt (1.5 equiv), CH2Cl2/DMF; (b) 20 % piperidine/DMF, 2  10 min; (c)
Fmoc-Arg(Boc)2-OH (1.5 equiv), DIC (1.5 equiv), HOBt (1.5 equiv), CH2Cl2/DMF.
Figure 2. Fmoc amino acids used as a spacer between the cationic
headgroup and the hydrophobic tail.
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Transfection compounds containing three arginines all bound
DNA (C5-8, D5-8, E5-7, F5-8, G5-7), except again
for two compounds with cholesterol tails (E8 and G8). Thus,
the binding activity of the cationic lipids increased as the
Scheme 2a
a Reagents and conditions: (a) Fmoc-Gly-OH (1.5 equiv), DIC (1.5 equiv), HOBt (1.5 equiv), CH2Cl2/DMF; (b) Fmoc-â-Ala-OH (1.5 equiv), DIC (1.5
equiv), HOBt (1.5 equiv), CH2Cl2/DMF; (c) Fmoc-ç-Abu-OH (1.5 equiv), DIC (1.5 equiv), HOBt (1.5 equiv), CH2Cl2/DMF; (d) Fmoc--Ahx-OH (1.5
equiv), DIC (1.5 equiv), HOBt (1.5 equiv), CH2Cl2/DMF; (e) 20% piperidine/DMF.
Scheme 3a
a Reagents and conditions: (a) For R ) R1-R4: (see Table 1, Figure 3, 2 equiv), DIC (2 equiv), HOBt (2 equiv), CH2Cl2/DMF. For R ) R4: cholesteryl
chloroformate (2 equiv), pyridine (4 equiv), DMAP (2 equiv), CH2Cl2/DMF. (b) 90 % TFA/CH2Cl2.
DNA Transfection Screening from Single Beads Journal of Combinatorial Chemistry, 2004, Vol. 6, No. 5 755
positive charge of the backbone increased, going from one
to three arginines in the headgroup, consistent with the
stronger electrostatic interaction with the negatively charged
DNA phosphate groups. Cationic lipids with cholesterol tails
tended to have weaker binding activity than those with
aliphatic tails.
Single-Bead Transfection Screening. To evaluate the
transfection activity of compounds derived from a single bead
(Table 1), the compounds were mixed with the lipid dioleyl
L-R-phosphatidylethanolamine (DOPE, 25 íg), vortexed, and
sonicated to form a liposome. DOPE was included as a co-
lipid with the cationic lipids used in this study because it
helps to promote a phase transition in liposomal structure,
which is thought to promote the escape of DNA from
transfection complexes when in the cytosol.18 The liposome
was mixed with plasmid DNA (0.1 íg) encoding â-galac-
tosidase, and the transfection activity was determined on the
human fibroblast cell line HEK293T. The assay was per-
formed on all the compounds simultaneously, determining
â-galactosidase enzymatic activity in a 96-well plate format,
and compared to commercially available transfection reagent
Effectene (Figure 5). Assays for â-galactosidase have the
advantage of there being little cellular background.
The majority of cationic lipids screened did not mediate
transfection under the conditions employed, but several of
the lipids did have significant transfection activity. A4 gave
a transfection level of 106%, as compared to the control
(100%). C4, D4, E4, G4, H4, A8, and C8 were able to
transfect HEK293T cells at 80% efficiency, as compared to
Effectene. Cholesterol derivatives with one, two, or three
arginines were clearly more active than those with aliphatic
tails, and some had an activity comparable to Effectene.
Cationic lipids containing a cholesterol tail and one or two
arginine headgroups gave higher transfection efficiencies than
those containing three arginine groups. The spacer did not
generally affect transfection efficiency for compounds with
one- or two-arginine groups and a cholesterol tail; however,
the transfection efficiency of the tri-arginine derivatives
decreased when the length of spacer increased (Figure 5).
The transfection patterns observed above relate not only to
DNA delivery efficiency but also to cell toxicity, and thus,
Figure 3. Carboxylic acids (hydrophobic tails) used for the synthesis of the transfection compound library.
Figure 4. Single-bead gel retardation assay (pEGFPLuc, 0.1 íg) complexes; lanes marked “c”) control, DNA without cationic lipid. The
presence of a band below the well indicates that the DNA has migrated and, thus, has not been bound by the transfection compound.
Table 1. Cationic Lipids Generated from Scheme 3
compounda 1 2 3 4 5 6 7 8
A Arg, n 1 1 1 1 2 2 2 2
spacer, m 0 0 0 0 3 3 3 3
tail, R C14 C16 C18 Chol C14 C16 C18 Chol
B Arg, n 1 1 1 1 2 2 2 2
spacer, m 1 1 1 1 5 5 5 5
tail, R C14 C16 C18 Chol C14 C16 C18 Chol
C Arg, n 1 1 1 1 3 3 3 3
spacer, m 2 2 2 2 0 0 0 0
tail, R C14 C16 C18 Chol C14 C16 C18 Chol
D Arg, n 1 1 1 1 3 3 3 3
spacer, m 3 3 3 3 1 1 1 1
tail, R C14 C16 C18 Chol C14 C16 C18 Chol
E Arg, n 1 1 1 1 3 3 3 3
spacer, m 5 5 5 5 2 2 2 2
tail, R C14 C16 C18 Chol C14 C16 C18 Chol
F Arg, n 2 2 2 2 3 3 3 3
spacer, m 0 0 0 0 3 3 3 3
tail, R C14 C16 C18 Chol C14 C16 C18 Chol
G Arg, n 2 2 2 2 3 3 3 3
spacer, m 1 1 1 1 5 5 5 5
tail, R C14 C16 C18 Chol C14 C16 C18 Chol
H Arg, n 2 2 2 2
spacer, m 2 2 2 2 - - - -
tail, R C14 C16 C18 Chol
a n ) number of arginine units, m ) number of methylene units
in spacer (m ) 0, compound without linker), R ) hydrophobic
tails.
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some of the compounds that did not produce efficient
transfection were observed microscopically to cause cell
death, presumably through a detergent-type activity disrupt-
ing the cell membranes. Compounds with a cholesterol tail
were observed to cause little toxicity, as compared to those
with aliphatic tails, compounds with three arginines, and long
spacer units being particularly toxic.
It should be noted that some of the most active compounds
with respect to transfection, containing one arginine and a
cholesterol tail, did not appear to bind DNA in the gel
retardation assay (Figure 4). This shows that it is important
not to discard potential transfection compounds on the basis
of this very widely used assay. The presence of DOPE in
the transfection assay may increase DNA binding activity
of these compounds, although we showed later that A4 has
significant transfection activity even without the addition of
the co-lipid DOPE (Figure 6).
Transfection Optimization. To optimize the transfection
efficiency, accurate quantification of the compounds was
needed. The synthesis of the cationic lipid series (A4-E4)
with the highest transfection activity was therefore scaled
up, and various parameters that could affect transfection
activity were investigated.
Different Cationic Lipid/DOPE Ratios. The formulation
of cationic liposomes (cationic lipid and co-lipid ratios) can
have a crucial effect on the transfection efficiency.19 Studies
on cells in culture clearly show that liposomes composed of
an equimolar mixture of co-lipid DOPE and cationic lipids
(e.g. N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammoni-
um chloride (DOTMA), 1,2-dioleyloxy-3-(trimethylammo-
nio)-propane (DOTAP)) can mediate higher levels of trans-
fection than those without DOPE or those with different
helper lipids, such as 1,2-dioleoyl-sn-glycero-3-phosphatid-
ylcholine (DOPC).20 In contrast, in vivo cholesterol-contain-
ing lipoplexes have shown higher biological activity, as
compared to complexes with DOPE.21 To maximize the
transfection activity of A4-E4, different ratios of cationic
lipids to DOPE were examined. Transfection was carried out
using four different cationic lipid/DOPE ratios (1:1, 1:2, 2:1,
and without DOPE). DOPE was usually important for these
compound libraries to obtain high transfection activity
(Figure 6), but A4 was an exception, giving high transfection
activity without DOPE. For four of the five lipids, a 2:1 ratio
of lipid/DOPE was optimal.
Liposome Formation. The method of liposome formula-
tion is undoubtedly important for transfection activity.22-24
DOPE and the cationic lipid were mixed in organic solvents,
the solvent was evaporated, and the dried film was resus-
pended in PBS by vortex-mixing to produce multilamellar
vesicles, which are broken by sonication into small unila-
mellar vesicles. The transfection activity of these two vesicle
forms, produced from our cationic lipids, was determined.
In both cases, cationic lipid was mixed with DOPE at a
weight ratio of 1:1. All the cationic liposomes gave higher
transfection efficiency when the liposomes were formulated
by vortex-mixing and sonication rather than by vortex-mixing
alone (Figure 7). Thus, for DOPE complexes with the
Figure 5. Transfection activities of synthetic compounds at the single-bead level. Liposomes from the compound and DOPE were mixed
with DNA and incubated with HEK293T cells for 48 h. Transfection activity was determined by a fluorimetric assay for â-galactosidase.
100% is the fluorescent signal from Effectene transfection and 0%, from control wells.
Figure 6. Effect of cationic lipid/DOPE ratio on transfection
activity. DOPE and five of the most active cationic lipids were
mixed at various ratios. Liposomes were formed, mixed with DNA,
and incubated with HEK293T cells for 48 h. Transfection activity
was determined by a fluorimetric assay for â-galactosidase. 100%
is the fluorescent signal from Effectene transfection and 0%, from
wells without transfection agent. Means from duplicate measure-
ments are shown (1 SD.
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cationic lipids containing one arginine group and a choles-
terol tail, small unilamellar vesicles were more active than
multilamellar vesicles.
DNA/Liposome Ratios. One reason the ratio of DNA to
liposome is important is because of the change in charge of
the lipoplexes. An overall positive charge promotes interac-
tion with the negatively charged cell surface. The liposomes
were therefore incubated with DNA at three different weight
ratios, and transfection activity was determined (Figure 8).
Changing the DNA ratio produced wide variations in
transfection activity. Although the five cationic lipids differed
only in the length of the spacer and had the same charge,
the effect of different DNA ratios varied greatly for different
lipids, suggesting that it is not simply the overall lipoplexes’
charge that determines the optimal ratio.
Overall, the results of the initial optimization of the
transfection activity of these compounds indicated that small
changes in liposome composition can have dramatic effects
on activity. Initial screens of libraries under one condition
may well miss transfection compounds that would be highly
active under other conditions. For the compounds synthesized
here with one arginine and a cholesterol tail, a lipid/DOPE
ratio of 2:1 and small unilamellar vesicles were best, but
clearly, optimal lipid/DNA ratios must be determined empiri-
cally.
Transfection Cytotoxicity. To assess the relationship
between cytotoxicity and gene expression efficiency, the
toxicity of the cationic lipids (A4-E4) was determined by
measuring changes in cell metabolic activity (MTT assay)25
(Figure 9). Cytotoxicity of A4-E4 was generally reduced
in the absence of DNA. A4, B4, and C4 showed little
cytotoxicity, but the cytotoxicity of D4 and E4 with the
longer spacers was slightly greater, but still comparable to
Effectene. Thus, this reduction in metabolic activity should
not inhibit the application of these transfection compounds.
In conclusion, a solid-phase approach to prepare libraries
of cationic lipids and assay compounds for transfection
activity at the single-bead level has been developed and
allowed members of the library to be identified that have
the potential to be better than many currently available
transfection reagents. Lipids with a one-arginine headgroup
and a cholesterol tail were found to be the most active, even
though their DNA binding strength was weak, as determined
by a gel-retardation assay, whereas they displayed minimal
cytotoxicity, showing that it is important not to discard
potential transfection compounds on the basis of this very
widely used assay. This approach enables libraries of
thousands of compounds to be rapidly prepared and screened
for potential in gene therapy applications. The efficient
screening of “spotting” compounds cleaved from single beads
into a microarray type format on a glass slide26 would allow
much faster analysis of transfection activity against different
cell-types, and this is an approach being developed and
showing much promise in our laboratories.
Experimental Section
General Information. Low-resolution mass spectra were
recorded on a VG platform quadrupole electrospray ioniza-
tion mass spectrometer. High-resolution electrospray mass
spectra were recorded on a Bruker Apex III FT-ICR mass
spectrometer. Reversed-phase analytical HPLC (RP-HPLC)
was performed using a Hewlett-Packard HP1100 Chemsta-
tion, equipped with a Phenomenex C18 prodigy 5-ím (150
mm  3.0 mm i.d.) column, with an ELS detector. Starting
materials and reagents were purchased from commercial
Figure 7. Effect of liposome formulation on transfection activity.
Liposomes from five of the most active cationic lipids and DOPE
were formed (a) by vortex-mixing alone, or (b) by sonication after
vortex-mixing. Lipoplexes that were formed by mixing the lipo-
somes and DNA were incubated with HEK293T cells for 48 h.
Transfection activity was determined by a fluorimetric assay for
â-galactosidase. 100% is the fluorescent signal from Effectene
transfection and 0% from wells without transfection. Means from
duplicate measurements are shown (1 SD.
Figure 8. Effect of DNA/cationic lipid ratio on transfection
activity. Liposomes of cationic lipid and DOPE were mixed with
DNA at various DNA/cationic lipid ratios (w/w) and incubated with
HEK293T cells for 48 h. Means from duplicate measurements are
shown (1 SD.
Figure 9. Effect of transfection compounds on cell metabolic
activity. Liposomes of cationic lipid and DOPE were formed and
added with or without DNA to HEK293T cells for 24 h. Cell
metabolic activity was determined by an MTT assay.
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suppliers and used without further purification. High-loading
beads (2) were synthesized according to published proce-
dures.8
Synthesis of Transfection Compounds on High-Loading
Beads. 1. Attachment of the Fmoc Knorr Linker onto
High-Loading Beads. The Fmoc Knorr linker (3) (0.44 g,
0.81 mmol) was dissolved in CH2Cl2/DMF (2:1, 4 mL). DIC
(0.13 mL, 0.81 mmol) and HOBt (0.11 g, 0.81 mmol) were
added. This mixture was left to stand for 10 min. This
solution was then added to aminomethyl polystyrene high-
loading dendrimer resin generation 1.0 (2) (0.16 g, 0.54
mmol), and the suspension was shaken overnight. The
resulting resin was washed with CH2Cl2, DMF, MeOH,
DMF, and CH2Cl2 (3  2 mL each) and dried under vacuum.
2. Synthesis of Arginine Scaffold-Bound Resin (5-7).
The mono-arginine scaffold resin 5 was synthesized by the
coupling of resin 4 (0.28 g, 0.45 mmol) with Fmoc-Arg-
(Boc)2-OH (0.46 g, 0.77 mmol), DIC (0.12 mL, 0.77 mmol),
and HOBt (0.10 g, 0.77 mmol) in CH2Cl2/DMF (2:1, 4 mL).
This resin was treated with 20% piperidine in DMF (5 mL)
for 10 min. The resulting resin was washed with DMF,
MeOH, and CH2Cl2 (3  5 mL each) and dried under
vacuum to give resin 5. Bis-arginine resin 6 was prepared
by reacting resin 5 (0.38 g, 0.46 mmol) with Fmoc-Arg-
(Boc)2-OH (0.42 g, 0.70 mmol) using DIC (0.11 mL, 0.70
mmol) and HOBt (0.09 g, 0.70 mmol) in CH2Cl2/DMF (2:
1, 4 mL). The Fmoc protecting group was removed to afford
resin 6. This synthetic method was repeated for preparation
of tris-arginine scaffold bound resin 7.
3. Synthesis of Arginine Scaffold Bound Resin with
Spacer (8-11). These resins were synthesized according to
the general procedure for the coupling of Fmoc amino acids.
Typically, the spacer moiety was introduced by coupling to
the arginine scaffold resins 5-7 (35-45 mg) with a Fmoc
amino acid spacer (1.5 equiv) (Figure 2) using DIC (1.5
equiv) and HOBt (1.5 equiv) in CH2Cl2/DMF (2:1, 2 mL).
The resulting resins were then Fmoc-deprotected by treating
with 20% piperidine in DMF. These resins were washed with
DMF, MeOH, and CH2Cl2 (3  2 mL each) and dried under
vacuum.
4. Synthesis of Arginine-Containing Cationic Lipo-
somes without Spacer (A1-4, F1-4 and C5-8). These
compounds were synthesized as shown in Scheme 3. The
resins 5-7 (5-7 mg) were reacted with the carboxylic acids
(Figure 3) (2 equiv), DIC (2 equiv), and HOBt (2 equiv) in
CH2Cl2/DMF (5:1, 0.5 mL). The suspension was shaken for
2 h and washed with CH2Cl2, MeOH, DMF, MeOH, and
CH2Cl2 (3  0.5 mL each) and dried under vacuum for 2 h.
Where the hydrophobic tail was cholesterol, the arginine
scaffold resins (5-7, 5-7 mg) were reacted with a solution
of cholesteryl chloroformate (2 equiv), pyridine (4 equiv),
and DMAP (2 equiv) in CH2Cl2/DMF (5:1, 0.5 mL), and
the suspension was shaken for 4 h. The resulting resin was
washed with CH2Cl2, MeOH, DMF, MeOH, and CH2Cl2 (3
 0.5 mL each) and dried under vacuum for 2 h. This resin
was reacted with a solution of 90% TFA in CH2Cl2 (0.2 mL).
The suspension was shaken for 2 h, and the cleaved product
in solution was collected. The solvents were removed in
vacuo and further dried for 2 h. The resulting products were
dissolved in MeOH/CH2Cl2, filtered through cotton wool,
and dried under vacuum for 2 h.
5. Synthesis of Arginine-Containing Cationic Lipo-
somes with Spacers (B1-8, C1-8, D1-8, E1-8, F5-8, G1-8,
and H1-4). The syntheses of these compounds were per-
formed as described above, with the exception that the
starting materials used were resin 8-11 (Scheme 3), which
contained a spacer.
Cleavage of Compounds from the Resin. The resin (1
bead) was loaded into a 200-íL vial insert, which was placed
in a 1.5-mL vial. A solution of 90% TFA/CH2Cl2 (50 íL)
was added, and the vial was sealed with a cap and shaken
for 2 h. The solvents were removed under vacuum. The
resulting product was redissolved in MeOH (2  0.1 mL)
and filtered by passing through cotton wool. The solvent was
removed under a stream of nitrogen, and the desired product
was further dried under vacuum for 2 h.
Gel-Retardation Assay. Plasmid DNA (pEGFPLuc, 1 íL,
0.1 íg/íL) was incubated with the single-bead (36 nmol/
bead) cleaved compound in 4 íL of phosphate buffered saline
(PBS) (pH 7.4) for 30 min. The DNA/cationic lipid complex
was mixed with 40% (w/v) sucrose in water (5 íL) and
loaded onto a 1% agarose gel (0.5 TBE buffer). The gel
was run at 200 V, 400 mA for 90 min, and the DNA bands
were visualized by ethidium bromide staining.
Single-Bead Transfection Screening. 1. Liposome For-
mation. DOPE (10 íL, 25 íg/10 íL) in CHCl3 was added
to the dry compound cleaved from single beads, and the
organic solvent was removed under vacuum (not less than 2
h). The resulting film was hydrated with PBS buffer (10 íL,
pH 7.4) at room temperature for 1 h. The liposome was then
sonicated at room temperature for 2  20 min and stored at
4 °C for 24 h prior to use.
2. Transfection of HEK293T Cells. HEK293T (human
embryonic kidney) cells were grown in DMEM supple-
mented with 10% heat-inactivated fetal calf serum, penicillin
(100 units/mL), streptomycin (100 íg/mL), and L-glutamine
(4 mM) at 37 °C under 5% CO2. For transfection, 1.8  104
cells/well were seeded in medium (140 íL) in a 96-well
culture plate to give 50-70% confluency for use the next
day. The growth medium was removed and replaced with
100 íL of serum-free medium (AIM-V, Sigma). Liposome
complexes (10 íL) were added to plasmid DNA (encoding
â-galactosidase, 0.2 íL, 0.5 íg/íL) and incubated at room
temperature for 30 min. DNA/liposome complexes were
added to the cells (10 íL/well contained DNA 0.1 íg/well),
and the cells were incubated at 37 °C under 5% CO2 for 48
h without removing the transfection mixture. For transfec-
tions with Effectene (Qiagen), enhancer (1.6 íL) was added
to plasmid DNA (0.2 íg, 0.5 íL) in EC buffer (60 íL). The
mixture was vortexed for 2 s. After 3 min, 5 íL Effectene
was added and the mixture was vortexed for 10 s. After 7
min, serum-free medium (350 íL) was added, the mixture
was mixed by pipette (up and down twice), and 50 íL of
DNA/Effectene complex was added to the cells in each well.
â-Galactosidase expression was determined with the Fluo-
Reporter LacZ/Galactosidase Quantitation kit (Molecular
Probes) according to the manufacturer’s instructions, with
the reaction developed for 10 min at room temperature.
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Transfection efficiency was calculated as a percentage
relative to the commercially available transfection reagent
Effectene, after subtracting the value of untransfected cells.
Transfection Cytotoxicity. Cytotoxicity was evaluated
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide reagent (MTT test). Cells were seeded in 96-well
plates at 1  104 cells/well. The growth medium was
removed the next day and replaced with 100 íL of serum-
free medium (AIM-V, Sigma). Cationic liposome/DNA
complexes and Effectene were prepared as described in the
transfection procedure and added to duplicate wells and the
plates were incubated at 37 °C under 5% CO2 for 24 h. The
medium was then removed and replaced with a phenol red-
free medium (90 íL). MTT (3 mg/mL) was added (10 íL/
well) to the cells, followed by MTT solubilization solution
(Sigma) (100 íL) to dissolve the resulting crystals, and the
absorbance was measured at 570 nm on a microplate reader
(Bio-Rad). The change in metabolic activity was calculated
as (A570 with compound/A570 without compound).
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